Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2017

Mar 31, 2017

35334_dirs_2017-03-31_1cf48190-6771-40cc-a3d4-acf211f99834.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-08-17

Reporting Person: Appelrouth Stewart (Director)